In early 2015, AngioDesign (UK) Ltd acquired the intellectual property rights to a C-domain-selective ACE inhibitor from the University of Cape Town. A Research Agreement between AngioDesign and UCT was signed off in September 2015.

In 2013, the University of Bath assigned its interests in two patent families relating to Angiotensin Converting Enzyme (ACE) to AngioDesign. These patents were based on the pioneering work of the AngioDesign founder members Professor Ravi Acharya at the University of Bath and Professor Edward Sturrock at the University of Cape Town to solve the crystal structures of the ACE N- and C-Domains alone and in combination with novel and existing ACE inhibitors.